Acquisitions once again remained in focus this week with Ablynx agreeing to be acquired by Sanofi SNY in a deal worth approximately €3.9 billion. Seattle Genetics SGEN also announced its intention to acquire Cascadian Therapeutics for …
Sanofi’s stock demonstrated the best return in the industry and among its major competitors. There are several catalysts for further growth in the stock’s value. Our DCF analysis shows that there is an upside opportunity of 17-54% from the …
In keeping with the commitment to dynamically provide members with timely information WallStEquities.com has issued …
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing …
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing …
After declining in 2016, share price of French pharma giant Sanofi SNY has picked up in 2017. This Zacks Rank #2 (Buy) stock has risen 21.1% this year so far, outperforming the return of the Zacks classified Large-Cap Pharma industry of …